With further stratified the subjects by age and sex, and there was still no significant difference in HCV status between those with and without metabolic syndrome. Moreover, the stage of liver fibrosis represented by aspartate aminotransferase to platelet ratio index was also not correlated with metabolic syndrome in the subjects with HCV infection. Conclusions: Although learn more subjects

with HCV infection had higher fasting glucose levels and lower cholesterol and triglyceride levels compared to those without HCV infection, HCV infection was not associated with metabolic syndrome based on the current diagnostic criteria irrespective of age, gender and the stage of hepatic fibrosis. Disclosures: The following people have nothing to disclose: Chien-Wei Su, Yuan-Jen Wang, Keng-Hsin Lan, Teh-Ia Huo, Yi-Hsiang Huang, Kuei-Chuan Lee, Han-Chieh Lin, Fa-Yauh Lee, Jaw-Ching Wu, Shou-Dong Lee Background: Treatment of hepatitis C virus (HCV) in patients co-infected with human immunodeficiency virus (HIV) has been limited by poor efficacy and frequent medication side effects. Protease inhibitors (PI) such as boceprevir and telaprevir improve

treatment results in clinical trials, but outcomes in large community-based HIV/ HCV populations are unknown. Aim: To describe the real-world effectiveness of boceprevir- or telaprevir-based therapies in HIV/HCV co-infection.

Methods: We identified HIV/HCV co-infected patients in the Veterans Affairs (VA) health care system nationally who initiated pegylated interferon BYL719 clinical trial (PEG) and ribavirin (Riba) with or without boceprevir or telaprevir from June 2011-November 2013 (n=134). Patients were followed until January 2014 to ascertain sustained virologic response (SVR). Results: Co-infected patients undergoing treatment had a mean age of 57.3 (SD 7) years and high baseline rates of comorbidities, including diabetes (18%), cirrhosis (28%), depression (54%), and alcohol use or dependence (40%). Few of any genotype (15-25%) completed more than 44 of 48 projected weeks. SVR was higher in genotype 1 patients receiving PI/PEG/Riba therapy (50.0% [95%CI 37-63]) versus PEG/Riba alone (33.3% [95%CI 20-47]) (Table MCE 1). Patients with genotypes 2/3 treated with PEG/Riba (n=24) achieved an SVR of 41.7% (95% CI 20-63). In multivariate analysis, PI/Peg/Riba therapy was the only characteristic independently associated with SVR in genotype 1 (AOR 2.2, 95% CI 1.1-4.7) after adjustment for genotype-treatment, cirrhosis, baseline HCV viral load, diabetes, and AST-to-platelet ratio. Conclusions: Therapy including boceprevir or telaprevir leads to higher SVR rates versus PEG/Riba in HIV/HCV co-infected patients in clinical practice.